Home » Stocks » MRUS

Merus N.V. (MRUS)

Stock Price: $22.00 USD -0.30 (-1.35%)
Updated May 13, 2021 1:51 PM EDT - Market open
Market Cap 856.15M
Revenue (ttm) 31.99M
Net Income (ttm) -79.17M
Shares Out 38.35M
EPS (ttm) -2.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $22.00
Previous Close $22.30
Change ($) -0.30
Change (%) -1.35%
Day's Open 22.41
Day's Range 20.41 - 23.02
Day's Volume 24,971
52-Week Range 10.18 - 31.27

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Merus N.V. (MRUS) delivered earnings and revenue surprises of -27.27% and -63.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 days ago - Zacks Investment Research

Clinical data update on zenocutuzumab selected for oral presentation at ASCO  MCLA-145 clinical update planned for 2H21  MCLA-129 first patient dosed in phase 1/2 trial  Cecile Geuijen, Ph.D., promoted ...

6 days ago - GlobeNewsWire

Merus' Fourth Sponsored Bispecific Antibody Currently in Clinical Trials Merus' Fourth Sponsored Bispecific Antibody Currently in Clinical Trials

1 week ago - GlobeNewsWire

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovat...

2 weeks ago - GlobeNewsWire

Merus N.V. (MRUS) delivered earnings and revenue surprises of -26.23% and 11.19%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Clinical data and program update planned for lead program zenocutuzumab (“Zeno”) in 2Q 2021

1 month ago - GlobeNewsWire

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovat...

2 months ago - GlobeNewsWire

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 08, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies...

2 months ago - GlobeNewsWire

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-lengt...

3 months ago - GlobeNewsWire

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-length...

3 months ago - GlobeNewsWire

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV...

Other stocks mentioned: ACRS, CYAD, GRTS, NERV, TENX
3 months ago - Benzinga

INDIANAPOLIS and UTRECHT, The Netherlands, Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a c...

Other stocks mentioned: LLY
3 months ago - PRNewsWire

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies...

4 months ago - GlobeNewsWire

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovati...

4 months ago - GlobeNewsWire

The FDA bestows a Fast Track status to Merus' (MRUS) lead pipeline candidate, Zenocutuzumab, for treating metastatic solid tumors harboring NRG1 gene fusions. Shares rise.

4 months ago - Zacks Investment Research

NRG1 fusions are rare mutations in many types of solid tumors, including non-small cell lung cancer and pancreatic cancer NRG1 fusions are rare mutations in many types of solid tumors, including non-sma...

4 months ago - GlobeNewsWire

UTRECHT, The Netherlands and STAMFORD, Conn., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multi-specific antibodies ...

4 months ago - GlobeNewsWire

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Merus N.V.  (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies ...

5 months ago - GlobeNewsWire

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovati...

6 months ago - GlobeNewsWire

–Clinical data and program update planned for lead program Zenocutuzumab (“Zeno”) in 2Q 2021–– MCLA-129 expected to enter clinic in 2021 –

6 months ago - GlobeNewsWire

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- myTomorrows, a global health technology company, and Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company develo...

7 months ago - GlobeNewsWire

Merus (MRUS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Merus N.V.  (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibod...

9 months ago - GlobeNewsWire

– Lead program Zenocutuzumab remains on track –– Dr. Andrew Joe appointed Chief Medical Officer –– Merus extends cash runway into 2H 2022 –

9 months ago - GlobeNewsWire

Dr. Joe brings seasoned research and development leadership and deep expertise in the clinical development of immuno-oncology, antibody, and targeted therapies for cancer Dr. Joe brings seasoned researc...

9 months ago - GlobeNewsWire

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibod...

9 months ago - GlobeNewsWire

Caris to provide DNA and RNA molecular testing to support  patient identification and enrollment for Merus’ Zenocutuzumab Phase 1/2 eNRGy trial

9 months ago - GlobeNewsWire

– MCLA-128, zenocutuzumab, independent epidemiology analysis reaffirms significant clinical and commercial potential in NRG1 fusion cancers –– MCLA-117 demonstrates limited clinical activity in Phase 1 ...

11 months ago - GlobeNewsWire

Merus NV (MRUS) delivered earnings and revenue surprises of -25.93% and -21.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Merus: Catalyst Filled 2020 For Biclonics Platform, Concerns Remain

1 year ago - Seeking Alpha

— Bill Lundberg, M.D., nominated for appointment as Chief Executive Officer —— Ton Logtenberg, Ph.D., to step down after 16 years of leadership —— Transition to occur December 31, 2019 —

1 year ago - GlobeNewsWire

Merus N.V. (MRUS) delivered earnings and revenue surprises of 14.89% and 15.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the pri...

1 year ago - GlobeNewsWire

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the laun...

1 year ago - GlobeNewsWire

Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Molecular Targ...

1 year ago - GlobeNewsWire

With Breast Cancer Awareness Month drawing to a close and the San Antonio Breast Cancer Symposium on the horizon, stay alert for breaking news from companies developing new treatments.

Other stocks mentioned: MGNX, SGEN, ZYME
1 year ago - The Motley Fool

Company to host investor call on Monday, October 28th at 8:00AM ET Company to host investor call on Monday, October 28th at 8:00AM ET

1 year ago - GlobeNewsWire

Merus N.V. (MRUS) delivered earnings and revenue surprises of -5.56% and -27.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

UTRECHT, The Netherlands, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovativ...

1 year ago - GlobeNewsWire

Merus is looking like an interesting pick from a technical perspective.

1 year ago - Zacks Investment Research

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Merus N.V. (MRUS).

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Merus.

2 years ago - Zacks Investment Research

Merus is demonstrating strong trading analytics amid the recent market hiccup relating to Dr. Gottlieb's sudden departure.

2 years ago - Seeking Alpha

About MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-1... [Read more...]

Industry
Biotechnology
IPO Date
May 19, 2016
CEO
Sven Lundberg
Employees
93
Stock Exchange
NASDAQ
Ticker Symbol
MRUS
Full Company Profile

Financial Performance

In 2020, Merus N.V.'s revenue was $29.94 million, a decrease of -3.82% compared to the previous year's $31.13 million. Losses were -$85.51 million, 55.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Merus N.V. stock is "Buy." The 12-month stock price forecast is 27.88, which is an increase of 26.73% from the latest price.

Price Target
$27.88
(26.73% upside)
Analyst Consensus: Buy